Anticancer Drugs Olaparib Oncology Pharmacology Physiotherapy

Olaparib (Clinical Trials Experience-5)

In this article, we will discuss Olaparib (Clinical Trials Experience-5). So, let’s get started.

Adverse reactions led to dose interruptions in 35% of those receiving Olparib and 10% of those receiving placebo; dose reductions in 26% of Olparib and 4% of placebo; and discontinuation in 6% of OlparibĀ and 2% in placebo.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.